SUNITINIB

Sunitinib is a multi-tyrosine kinase inhibitor and is FDA-approved for the treatment of metastatic renal carcinoma, imatinib-resistant gastrointestinal tumour and pancreatic neuroendocrine tumours. Cutaneous adverse effects attributed to sunitinib include hand-foot syndrome , seborrheic dermatitis-like or maculopapular rash, changes in hair color, yellowish skin discoloration, splinter hemorrhages, and a scrotal rash [JEADV 2016;30;132].

RegionalDerm

Homepage | FAQs | Contact Dr. White


It is not the intention of RegionalDerm.com to provide specific medical advice, diagnosis or treatment. RegionalDerm.com only intends to provide users with information regarding various medical conditions for educational purposes and will not provide specific medical advice. Information on RegionalDerm.com is not intended as a substitute for seeking medical treatment and you should always seek the advice of a qualified healthcare provider for diagnosis and for answers to your individual questions. Information contained on RegionalDerm.com should never cause you to disregard professional medical advice or delay seeking treatment. If you live in the United States and believe you are having a medical emergency call 911 immediately.